Citation Impact
Citing Papers
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
2015
Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis
2018
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
2015
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
2014
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
2017
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Precision oncology in the age of integrative genomics
2018
PARP inhibitor combination therapy
2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
Pancreatic cancer
2020 Standout
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
2013
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Olaparib: First Global Approval
2015
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Multiparametric Analysis of Cell-Free DNA in Melanoma Patients
2012
Pancreatic cancer
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
High speed of fork progression induces DNA replication stress and genomic instability
2018 Nature
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
2016
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2017
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
2013
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
Oxidative Stress in Cancer
2020 Standout
Synthetic lethality: the road to novel therapies for breast cancer
2016
The ChEMBL database in 2017
2016 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Targeting the RAS pathway in melanoma
2011
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
2016
ROS and the DNA damage response in cancer
2018 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
An analysis of the attrition of drug candidates from four major pharmaceutical companies
2015 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
2011
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Applications of Fluorine in Medicinal Chemistry
2015 Standout
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
UV Radiation and the Skin
2013 Standout
Works of Maria Orr being referenced
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples
2010
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
2009
Circulating tumour-derived predictive biomarkers in oncology
2010
Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour
2014
435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
2015
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
2013
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition
2015